List of Excipients in Branded Drug APREMILAST

Generic Drugs Containing APREMILAST

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	apremilast	31722-085	CELLULOSE, MICROCRYSTALLINE
Camber Pharmaceuticals Inc	apremilast	31722-085	CROSCARMELLOSE SODIUM
Camber Pharmaceuticals Inc	apremilast	31722-085	LACTOSE MONOHYDRATE
Camber Pharmaceuticals Inc	apremilast	31722-085	MAGNESIUM STEARATE
Camber Pharmaceuticals Inc	apremilast	31722-085	POLYETHYLENE GLYCOL 4000

What are the Most Frequently-Used Excipients in APREMILAST?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL 4000

Apremilast Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Apremilast is an oral, small-molecule phosphodiesterase-4 inhibitor marketed in the United States as Otezla. Its commercial formulation is an immediate-release, film-coated tablet in 10 mg, 20 mg, and 30 mg strengths. The strongest excipient opportunities are in generic-tablet supply, film coating, low-dose content uniformity, titration packaging, alternate oral dosage forms, and regional manufacturing. Biosimilar risk does not apply because apremilast is a chemically synthesized small molecule, not a biologic.[1]

What is apremilast and how is it formulated?

Apremilast is approved for plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. The product is administered orally, with a five-day titration schedule followed by a 30 mg twice-daily maintenance dose for most adult indications.[1]

Attribute	Commercial profile
Active ingredient	Apremilast
Drug class	PDE4 inhibitor
Reference product	Otezla
Original U.S. applicant	Celgene
Current commercial owner	Amgen
FDA approval	2014
Dosage form	Immediate-release film-coated tablet
Strengths	10 mg, 20 mg, 30 mg
Maintenance regimen	30 mg twice daily
Primary markets	Psoriasis, psoriatic arthritis, Behçet's disease
Biosimilar pathway	Not applicable
Generic pathway	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act

The Otezla label identifies lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, polyvinyl alcohol, titanium dioxide, talc, magnesium stearate, and iron oxides among the inactive ingredients. Colorants vary by tablet strength.[1]

This composition is commercially significant because it relies on widely available compendial excipients. A generic manufacturer does not need an exotic solubilizer, lipid system, polymeric matrix, or device-dependent delivery platform to reproduce the reference dosage form.

What excipients are used in Otezla tablets?

The main excipient functions are predictable for an immediate-release tablet.

Excipient or excipient class	Likely function	Commercial implication
Lactose monohydrate	Diluent and compactability aid	Large-volume, price-sensitive supply market
Microcrystalline cellulose	Diluent, dry binder, disintegration support	Opportunity for grade optimization
Croscarmellose sodium	Superdisintegrant	Critical to rapid tablet breakup
Magnesium stearate	Lubricant	Requires control of blending time and surface coverage
Polyvinyl alcohol	Film-forming coating polymer	Opportunity for coating-system suppliers
Titanium dioxide	Opacifier and pigment	Regulatory and regional substitution issues
Talc	Anti-tacking and coating aid	Standard film-coating input
Iron oxides	Tablet color differentiation	Relevant to strength identification and global compliance

The low-dose 10 mg tablet creates the most demanding content-uniformity problem. The active pharmaceutical ingredient represents a smaller percentage of tablet mass than it does in the 30 mg tablet. Blend segregation, particle-size mismatch, electrostatic charging, and over-lubrication can therefore affect dose uniformity and dissolution.

Which excipient properties matter most?

Particle-size distribution, bulk density, flow, moisture content, and surface morphology are central to process performance. Suppliers that can provide consistent lactose, microcrystalline cellulose, and croscarmellose grades have a stronger value proposition than suppliers competing only on unit price.

Magnesium stearate requires particular process control. Excessive lubrication can reduce tablet tensile strength and slow dissolution. The risk increases when manufacturers use high-shear blending or extend lubricant mixing to compensate for poor powder flow.

Film-coating systems must provide:

• Uniform color across three strengths
• Adequate tablet protection
• Low friability
• Reliable coating weight gain
• Acceptable appearance after transport
• Compatibility with the selected pigments and titanium dioxide alternatives

How should a generic apremilast formulation be designed?

The most efficient generic strategy is usually a Q1/Q2-oriented immediate-release film-coated tablet using the reference product's established excipient architecture. The objective is not necessarily to copy every manufacturing parameter. It is to match critical quality attributes, including dissolution, assay, content uniformity, impurities, hardness, friability, and stability.

Recommended formulation strategy

A practical development sequence is:

1. Establish apremilast particle-size and polymorph controls.
2. Select lactose and microcrystalline cellulose grades that provide consistent flow and compaction.
3. Use croscarmellose sodium at a level sufficient to offset tablet hardness without delaying disintegration.
4. Optimize magnesium stearate addition time and concentration.
5. Develop a pigmented polyvinyl-alcohol coating system.
6. Test dissolution across physiological pH conditions.
7. Confirm stability under ICH long-term and accelerated conditions.
8. Validate the titration pack across all five introductory dose levels.

The active ingredient's solid-state form must be controlled because changes in polymorphism, particle size, or crystallinity can alter dissolution and bioavailability. A formulation that performs acceptably in a single medium may fail comparative dissolution in another medium.

Is a novel excipient required?

No. A conventional compendial excipient system is commercially plausible for an ANDA product. A novel excipient could add regulatory burden without providing a clear benefit unless it enables a differentiated product such as an orally disintegrating tablet, pediatric formulation, or improved low-dose manufacturing process.

What excipient opportunities exist for apremilast manufacturers?

Commodity excipient supply

The largest immediate opportunity is supply into generic manufacturing. Demand is likely to center on:

• Direct-compression lactose
• Microcrystalline cellulose
• Croscarmellose sodium
• Magnesium stearate
• Polyvinyl-alcohol coating systems
• Talc
• Titanium dioxide alternatives
• Iron oxide pigment systems

Because these materials are widely used in oral solid-dose manufacturing, apremilast alone will not create a large standalone market. The opportunity is to use apremilast as an anchor product in a broader supply agreement covering multiple generic tablets.

Functional excipient upgrades

Higher-value opportunities involve performance improvements rather than simple replacement. Examples include:

• Low-moisture lactose for improved stability
• Co-processed cellulose systems for better flow and compactability
• Engineered croscarmellose grades for faster disintegration
• Lubricant systems that reduce dissolution sensitivity
• Ready-to-use film-coating premixes
• Pigment systems that avoid regionally restricted or commercially difficult materials

A supplier that can reduce tablet weight, improve throughput, or narrow content-uniformity variability has a stronger negotiating position with generic manufacturers and contract development and manufacturing organizations.

Packaging and titration systems

The five-day initiation schedule creates a packaging opportunity. A titration pack may contain 10 mg, 20 mg, and 30 mg tablets arranged by day and dose. Commercial differentiation can come from:

• Calendar blister packs
• Unit-dose packaging
• Moisture-protective blister materials
• Patient-friendly labeling
• Hospital and specialty-pharmacy packaging
• Regional packs with language-specific instructions

Packaging is not an excipient strategy in the narrow regulatory sense, but it directly affects the product's commercial usability and manufacturing economics.

What formulations are protected by apremilast patents?

Apremilast patent analysis must distinguish among compound claims, polymorph or solid-state claims, formulations, methods of treatment, and regulatory exclusivity. A generic applicant evaluates the current FDA Orange Book listing, patent-use codes, litigation history, and any applicable settlement restrictions before filing an ANDA.[2]

The reference product's commercial tablet uses a conventional immediate-release formulation. That reduces the likelihood that a generic competitor must reproduce a highly specialized delivery mechanism. The principal formulation risks are therefore:

• Dissolution mismatch
• Content-uniformity failure, particularly for 10 mg tablets
• Solid-state differences
• Coating composition and color differences
• Stability failures
• Inability to support the complete titration regimen

An excipient change does not automatically avoid a patent claim. Patent scope depends on the claim language. A formulation patent may cover a specific excipient combination, concentration range, particle-size distribution, dissolution profile, or manufacturing process. A generic manufacturer must assess each claim independently.

When does apremilast lose exclusivity?

FDA approval for Otezla occurred in 2014, but market-entry timing depends on several separate rights:

Exclusivity or barrier	Relevance to apremilast
New chemical entity exclusivity	Applied to the original FDA approval period
Orange Book patents	May cover the drug, formulation, or approved methods
Pediatric exclusivity	Can extend certain listed protections when granted
Regulatory exclusivity for additional indications	May delay approval for specific uses
ANDA litigation	A timely Paragraph IV notice can trigger a 30-month stay
Settlement agreements	May establish a negotiated generic entry date
Non-U.S. rights	Depend on national patent and regulatory systems

The core commercial issue is no longer simply the expiration date of the original compound patent. Generic timing depends on the full Orange Book estate and the outcome of Paragraph IV litigation or settlement. FDA's Orange Book is the controlling source for currently listed U.S. patents and exclusivity information.[2]

What is the Orange Book and Paragraph IV risk for apremilast?

An ANDA applicant may certify that a listed patent has expired, will expire before approval, is not infringed, or is invalid. A Paragraph IV certification alleges that the patent is invalid, unenforceable, or not infringed. The applicant must notify the reference-product sponsor and patent owner.

The sponsor can file patent litigation within the statutory period. That action can impose a 30-month stay on final ANDA approval, subject to statutory exceptions and court developments. The commercial effect is material: a product can complete development and receive tentative approval while remaining unable to launch.

For apremilast, risk analysis should examine:

• Listed patent numbers and expiration dates
• Patent-use codes for psoriasis, psoriatic arthritis, and Behçet's disease
• Whether the ANDA includes a section viii statement carving out patented uses
• The existence of prior Paragraph IV notices
• District court outcomes
• Federal Circuit appeals
• Settlement terms and authorized-generic provisions
• Whether the applicant seeks all strengths and the full titration schedule

A narrow label carve-out may reduce method-of-use exposure but can also limit commercial positioning. For a drug with multiple indications, the value of a full label may justify litigation or licensing costs.

Which companies can challenge or compete with Otezla?

Competition falls into four groups:

1. Generic apremilast manufacturers filing ANDAs.
2. Authorized or licensed generic suppliers.
3. Oral small-molecule competitors in psoriasis and psoriatic arthritis.
4. Biologic manufacturers competing for the same patients.

Relevant competing therapies include biologic TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and other oral immunomodulators. Apremilast retains a commercial position as an oral, non-biologic option with no injection requirement and a comparatively simple distribution model.

Generic competition will likely focus on price, pharmacy availability, payer coverage, and supply reliability. A differentiated excipient system will not by itself preserve branded pricing after broad generic entry. Its value is in lowering manufacturing cost, preventing recalls, improving yield, or enabling a differentiated dosage form.

How strong is the apremilast formulation opportunity?

The formulation opportunity is moderate for conventional generics and higher for differentiated products.

Opportunity	Technical difficulty	Commercial potential
Conventional film-coated generic tablet	Low to moderate	High volume, low margin
Improved direct-compression process	Moderate	Moderate
Orally disintegrating tablet	Moderate to high	Selective
Pediatric liquid or dispersible tablet	High	Dependent on clinical demand
Abuse-deterrent or modified-release product	High	Low apparent rationale
Titration-pack optimization	Low to moderate	Moderate
Regional excipient substitution	Moderate	Moderate
Coated tablet with reduced titanium dioxide	Moderate	Regulatory and market dependent

An orally disintegrating tablet could improve administration for patients with swallowing difficulty, but it would require taste masking, mechanical-strength control, moisture protection, and new clinical and regulatory work. A liquid formulation could support pediatric use, yet apremilast's approved adult indications and the need to demonstrate a clinically useful population limit the immediate opportunity.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barriers are process consistency and regulatory comparability rather than access to raw materials. A viable supplier or generic developer must control:

• API particle-size distribution
• Powder segregation
• Low-dose blend uniformity
• Compression-force sensitivity
• Lubrication time
• Coating uniformity
• Pigment dispersion
• Moisture exposure
• Packaging protection
• Stability across global climate zones

IP barriers may arise from formulation patents, solid-state patents, manufacturing claims, and method-of-use claims. Excipient substitution can reduce infringement exposure only when the resulting product falls outside the relevant claim scope. It does not eliminate the need for a complete freedom-to-operate analysis.

What are the best commercial opportunities in apremilast?

The most attractive opportunities are:

• Supplying functional excipients to multiple ANDA developers
• Providing ready-to-use coating systems
• Developing low-variability blends for 10 mg tablets
• Contract manufacturing of titration packs
• Offering regional formulations that address pigment or excipient restrictions
• Developing an orally disintegrating or dispersible product
• Licensing formulation know-how to generic manufacturers
• Supporting stable supply in emerging markets

Revenue exposure will be highest for products that launch before broad generic erosion and for suppliers that secure multi-year agreements with several manufacturers. A single-product excipient contract is less attractive than a platform agreement covering apremilast and other immediate-release, low-dose tablets.

Key Takeaways

• Apremilast is an immediate-release, film-coated tablet with a conventional excipient system.
• The principal excipients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide, and iron oxides.
• The 10 mg strength presents the greatest content-uniformity and segregation risk.
• Generic manufacturers can likely pursue a conventional compendial formulation without a novel excipient.
• Higher-value opportunities include functional excipient grades, film-coating systems, titration packaging, and alternate oral dosage forms.
• Biosimilar competition is irrelevant because apremilast is a small molecule.
• Generic launch timing depends on current Orange Book listings, Paragraph IV litigation, use-code strategy, and settlement terms.
• The commercial opportunity is strongest in supply agreements and manufacturing services, not in commodity excipient sales alone.

FAQs

Can apremilast tablets be manufactured without lactose?

A lactose-free formulation is technically possible, but it would require redevelopment of flow, compaction, disintegration, dissolution, and stability characteristics. Mannitol, dibasic calcium phosphate, or alternative cellulose systems could be evaluated, subject to comparative performance and regulatory requirements.

Is an apremilast orally disintegrating tablet commercially attractive?

It could address swallowing difficulty and improve administration convenience, but taste masking, moisture sensitivity, tablet strength, and clinical positioning would determine whether the product supports a premium or meaningful market share.

Which excipient is most important for apremilast dissolution?

Croscarmellose sodium, tablet porosity, compression force, particle size, and magnesium-stearate exposure collectively affect dissolution. No single excipient should be treated as the sole dissolution-control variable.

Does changing the film coating avoid an apremilast formulation patent?

Not necessarily. Patent scope depends on the claims. A coating change may avoid a narrow coating claim but will not avoid claims directed to the active ingredient, tablet composition, dissolution profile, manufacturing process, or method of treatment.

Can a generic manufacturer launch only the 30 mg apremilast tablet?

A 30 mg-only product may be technically feasible, but the commercial product must address the approved titration regimen. A limited-strength launch can reduce manufacturing complexity while weakening pharmacy and payer substitution if the full starter schedule is unavailable.

References

1. U.S. Food and Drug Administration. (2024). Otezla (apremilast) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2014). FDA approves Otezla to treat psoriatic arthritis.
4. Amgen Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
5. European Medicines Agency. (2015). Otezla: EPAR - product information.